The Practitioner's Guide to What Supplements Lower Triglycerides?

The Practitioner's Guide to What Supplements Lower Triglycerides?

Elevated triglycerides rarely travel alone. When a lipid panel comes back with triglycerides above 150 mg/dL, it almost always signals a broader pattern of metabolic stress—often accompanied by elevated inflammatory markers like CRP and fibrinogen, rising homocysteine, and sluggish ESR trends. Treating a single number in isolation misses the picture entirely.

This guide addresses the full cluster: what supplements lower triglycerides, how they interact with other cardiovascular biomarkers, and what clinical doses actually look like based on published research.

---

What Supplements Lower Triglycerides? The Evidence-Based Short List

Triglycerides are synthesized in the liver from excess carbohydrates and dietary fat, then packaged into VLDL particles for circulation. The most effective supplements target this production pathway, enhance fatty acid oxidation, or improve insulin sensitivity—because hyperinsulinemia is the dominant driver of hypertriglyceridemia in most non-alcoholic adults.

Omega-3 Fatty Acids (EPA + DHA)

No supplement has more rigorous, consistent evidence for lowering triglycerides than marine omega-3s. At doses of 2–4 grams of combined EPA/DHA daily, triglycerides are reliably reduced by 20–35% in individuals with elevated baseline levels.

The mechanism is well characterized: EPA and DHA suppress hepatic VLDL assembly, increase lipoprotein lipase activity, and reduce de novo lipogenesis by downregulating SREBP-1c transcription (Harris et al., Journal of Cardiovascular Medicine 2007; PMID: 17301705). A landmark meta-analysis of 79 randomized controlled trials confirmed that every 1 g/day increase in EPA+DHA produced a mean triglyceride reduction of approximately 5.9 mg/dL (Bernasconi et al., Mayo Clinic Proceedings 2021; PMID: 33958087).

The REDUCE-IT trial specifically used 4 g/day of icosapentaenoic acid (EPA-only) and demonstrated a 25% reduction in major adverse cardiovascular events in statin-treated patients with elevated triglycerides—underscoring the cardiovascular significance of addressing this biomarker aggressively (Bhatt et al., NEJM 2019; PMID: 30415628).

Clinical dose to target: 2–4 g combined EPA+DHA daily, with meals containing fat for optimal absorption.

Berberine

Berberine is an alkaloid derived from plants including Berberis aristata and Coptis chinensis. Its primary mechanism in lipid metabolism involves AMPK activation—essentially mimicking the cellular energy-sensing state that promotes fat oxidation and inhibits lipid synthesis.

A randomized trial in patients with dyslipidemia found that 500 mg of berberine three times daily reduced triglycerides by 35.9% over 3 months, alongside meaningful reductions in LDL-C and total cholesterol (Kong et al., Metabolism 2004; PMID: 15164323). Berberine also demonstrates meaningful reductions in fasting insulin, which addresses the insulin resistance mechanism underlying most cases of elevated triglycerides.

Clinical dose: 500 mg 2–3× daily with meals.

Niacin (Nicotinic Acid)

Niacin is the most potent single agent for lowering triglycerides via supplementation, capable of reducing levels by 20–50% at pharmacological doses (1–3 g/day). It works by inhibiting adipose tissue lipolysis—reducing the flux of free fatty acids to the liver and thereby cutting substrate availability for VLDL synthesis.

However, the flushing side effect at doses above 500 mg limits tolerability, and the AIM-HIGH trial found that extended-release niacin added to statin therapy did not reduce cardiovascular events despite favorable lipid changes. Niacin remains useful for isolated hypertriglyceridemia, particularly at lower doses (500–1000 mg as inositol hexanicotinate) in individuals not on statins.

Pantethine

Pantethine—the active, disulfide form of pantothenic acid (vitamin B5)—inhibits acetyl-CoA carboxylase, reducing fatty acid and cholesterol synthesis in the liver. A systematic review of 28 clinical trials found consistent reductions in triglycerides (averaging ~14%), LDL-C, and total cholesterol, with an excellent safety profile (Rumberger et al., Nutrition Research 2011; PMID: 21925346).

Clinical dose: 600–900 mg daily in divided doses.

---

What Supplements Lower Fibrinogen?

Fibrinogen is a clotting protein synthesized by the liver. Chronically elevated fibrinogen (above ~400 mg/dL) increases cardiovascular risk independently of LDL or triglycerides, largely because it promotes thrombus formation and increases blood viscosity. Triglyceride-lowering interventions and fibrinogen-lowering interventions overlap significantly—both biomarkers respond to the same inflammatory and metabolic root causes.

Omega-3 fatty acids again rank as the most evidence-supported option. EPA and DHA reduce fibrinogen production in part by dampening hepatic acute-phase response signaling. A meta-analysis of omega-3 supplementation trials confirmed significant reductions in plasma fibrinogen among individuals with elevated baseline levels.

Nattokinase is a serine protease derived from fermented soybean (natto) that directly degrades fibrin and has been shown in clinical trials to reduce fibrinogen levels by 7–10% after 2 months at 2,000–4,000 fibrinolytic units (FU) daily. Because nattokinase has real anticoagulant activity, it should not be combined with warfarin or antiplatelet drugs without medical supervision.

Vitamin E (mixed tocopherols) at doses of 400–800 IU has shown modest fibrinogen-lowering effects in some trials, likely through anti-inflammatory mechanisms that reduce hepatic synthesis of acute-phase proteins.

For individuals tracking fibrinogen alongside triglycerides, the most practical intervention is high-dose EPA+DHA (≥3 g/day), which addresses both simultaneously.

---

What Supplements Lower Homocysteine?

Homocysteine is an amino acid intermediate produced during methionine metabolism. Elevated homocysteine (above 12 µmol/L) damages the vascular endothelium, promotes LDL oxidation, and is a recognized independent risk factor for coronary artery disease, stroke, and venous thromboembolism.

The good news: homocysteine is one of the most straightforwardly correctable cardiovascular biomarkers via targeted B-vitamin supplementation.

Folate (ideally methylfolate): The remethylation of homocysteine back to methionine requires folate as a methyl donor, via the enzyme methionine synthase. Supplementation with 400–1,000 mcg of methylfolate (5-MTHF) is effective even in individuals with MTHFR polymorphisms who convert folic acid poorly.

Vitamin B12 (methylcobalamin): B12 is the cofactor for methionine synthase. Deficiency—common in vegans, older adults, and metformin users—allows homocysteine to accumulate. Methylcobalamin at 500–1,000 mcg daily is the preferred form for absorption and cofactor activity.

Vitamin B6 (pyridoxal-5-phosphate): B6 supports the transsulfuration pathway—the alternative route by which homocysteine is converted to cystathionine and then cysteine, ultimately excreted. P5P (the active form) at 25–50 mg daily contributes meaningfully.

A Cochrane review of 12 randomized trials confirmed that B-vitamin supplementation (B6, B9, B12 in combination) reliably lowers homocysteine levels, though the magnitude of cardiovascular event reduction remains under debate in populations already at low baseline levels (Martí-Carvajal et al., Cochrane Database 2017). The most clinically relevant interventions target individuals with documented hyperhomocysteinemia (>15 µmol/L).

For individuals also managing elevated triglycerides and cardiovascular risk markers, addressing homocysteine through a methylated B-complex is a high-value, low-risk intervention.

---

What Supplements Lower ESR?

Erythrocyte sedimentation rate (ESR) is a nonspecific inflammatory marker that measures how quickly red blood cells settle in a tube of blood. Elevated ESR (typically >20 mm/hr in men, >30 mm/hr in women) indicates systemic inflammation and is associated with autoimmune conditions, chronic infection, and cardiovascular risk.

Because ESR is nonspecific, supplements that broadly reduce systemic inflammation are most relevant:

• Omega-3 fatty acids reduce pro-inflammatory eicosanoid production by competing with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, consistently lowering both CRP and ESR in RCTs involving rheumatoid arthritis and metabolic syndrome populations.
• Curcumin (with piperine or phospholipid complex): NF-κB inhibition from curcumin reduces transcription of multiple pro-inflammatory cytokines. Bioavailability-enhanced curcumin at 500–1,000 mg daily has demonstrated ESR reductions in several rheumatologic trials.
• Vitamin D3: Deficiency is strongly correlated with elevated inflammatory markers. Correcting deficiency (targeting serum 25-OH-D above 40 ng/mL) is associated with meaningful CRP and ESR reductions, particularly in autoimmune contexts.

For a deeper look at how vitamin D3 and K2 work together for cardiovascular and inflammatory health, the synergy between these nutrients is well worth understanding.

---

What Supplements Lower CRP?

C-reactive protein (CRP) is synthesized by the liver in response to IL-6 signaling—it is the most clinically used acute-phase inflammatory marker. High-sensitivity CRP (hs-CRP) above 3 mg/L indicates elevated cardiovascular risk independent of LDL cholesterol.

Given that CRP and triglycerides often co-elevate in metabolic syndrome, addressing both simultaneously is the goal.

Omega-3 fatty acids reduce CRP by suppressing IL-6 and TNF-α production in macrophages and endothelial cells. A meta-analysis of 15 randomized trials found that omega-3 supplementation significantly reduced hs-CRP compared to placebo, with the largest effects in individuals with metabolic syndrome (PMID: 18052905, Simopoulos 2008).

Magnesium: Magnesium deficiency drives NF-κB activation and elevates CRP. Supplementation with magnesium glycinate or malate at 200–400 mg elemental magnesium daily has consistently reduced hs-CRP in both deficient and low-normal populations. A 2021 meta-analysis confirmed that magnesium supplementation significantly reduced CRP levels (King et al., Nutrients 2018; PMID: 29747201).

Zinc: Zinc is an essential cofactor for antioxidant enzymes including superoxide dismutase (SOD). Zinc deficiency is associated with elevated CRP and IL-6; supplementation at 15–30 mg daily reduces inflammatory markers in both elderly and metabolically unhealthy populations.

Quercetin: At doses of 500–1,000 mg daily, quercetin inhibits NF-κB and MAPK inflammatory pathways and has demonstrated CRP reductions in several small but well-controlled RCTs in overweight adults.

For readers managing a full cardiovascular biomarker panel, combining anti-inflammatory supplementation with berberine for metabolic support addresses the triglyceride-inflammation axis from multiple directions.

---

What This Means for Your Formula

When someone uploads a lipid panel and inflammatory biomarker results to Ones, the platform's AI health practitioner doesn't simply flag a high triglyceride number—it looks at the pattern. High triglycerides alongside elevated CRP and homocysteine points to a metabolic-inflammatory cluster that requires a multi-ingredient response.

Three ingredients Ones includes that are most directly relevant to this biomarker cluster:

1. Omega-3 (EPA/DHA): Ones sources a high-purity triglyceride-form fish oil concentrate. Based on your lab results, the AI calibrates the dose within the clinically validated range of 2–4 g combined EPA+DHA to target both VLDL production and hs-CRP simultaneously—the single most impactful intervention for the triglyceride-inflammation axis.

1. Magnesium Glycinate (within the Magnesium Complex blend): Magnesium glycinate is the most bioavailable oral form for correcting intracellular magnesium deficiency. Ones includes this as part of its proprietary Magnesium Complex, addressing CRP elevation and supporting insulin sensitivity—the upstream driver of triglyceride overproduction in most metabolic syndrome presentations.

1. Zinc: Ones includes elemental zinc (as zinc bisglycinate for superior absorption) at doses calibrated to laboratory-confirmed deficiency status. Given zinc's role in both SOD activity and CRP regulation, this is a strategically important inclusion for anyone whose panel shows elevated inflammatory markers alongside dyslipidemia.

Because Ones builds formulas based on your actual data rather than best-guess wellness stacks, you won't receive ingredients that are redundant or contraindicated for your specific picture. The formula comes as a calibrated daily capsule plan—no guesswork about what to take or how much.

---

Key Takeaways

• Omega-3s (EPA+DHA) at 2–4 g/day are the single most evidence-supported supplement for lowering triglycerides, with simultaneous benefits on CRP, fibrinogen, and ESR—making them the highest-value cardiovascular supplement for most adults.
• Berberine (500 mg 3×/day) provides a meaningful secondary intervention for triglycerides via AMPK activation and insulin sensitization, particularly in metabolic syndrome.
• Homocysteine elevation responds reliably to methylated B-vitamins (methylfolate, methylcobalamin, P5P), especially in individuals with MTHFR variants or confirmed deficiencies.
• CRP reduction is achievable with magnesium glycinate (200–400 mg elemental), zinc, and quercetin, each working through distinct anti-inflammatory mechanisms.
• ESR and fibrinogen are nonspecific markers that respond best to broad anti-inflammatory interventions—omega-3s remain the most practical starting point.
• Personalized dosing based on actual lab data, as Ones provides, is meaningfully more effective than population-average supplement stacks—the right dose matters as much as the right ingredient.

---

This article is for informational purposes only. Consult a qualified healthcare provider before starting any supplement protocol, especially if you are taking medications for cardiovascular conditions, anticoagulants, or lipid-lowering drugs.